CL2010000434A1 - Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica. - Google Patents

Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.

Info

Publication number
CL2010000434A1
CL2010000434A1 CL2010000434A CL2010000434A CL2010000434A1 CL 2010000434 A1 CL2010000434 A1 CL 2010000434A1 CL 2010000434 A CL2010000434 A CL 2010000434A CL 2010000434 A CL2010000434 A CL 2010000434A CL 2010000434 A1 CL2010000434 A1 CL 2010000434A1
Authority
CL
Chile
Prior art keywords
vitamin
pharmaceutical composition
hydroxybenzoyl
deficiency
salts
Prior art date
Application number
CL2010000434A
Other languages
English (en)
Inventor
Cristina Castelli
Laura Kragie
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000434(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of CL2010000434A1 publication Critical patent/CL2010000434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTA RELACIONADA CON EL USO DE UNA COMPOSICIÓN FARMACÉUTICA ORAL QUE COMPRENDE (1) VITAMINA B12 Y (2) UN COMPUESTO SELECCIONADO DEL ÁCIDO N-[8-(2- HIDROXIBENZOIL)AMINO]CAPRÍLICO Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES, EN DONDE DICHA COMPOSICIÓN FARMACÉUTICA SIRVE PARA LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL PARA TRATAR LA DEFICIENCIA DE VITAMINA B12 EN UN SUJETO QUE LO NECESITA.        
CL2010000434A 2007-11-02 2010-04-30 Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica. CL2010000434A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US2010808P 2008-01-09 2008-01-09
US8356608P 2008-07-25 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
CL2010000434A1 true CL2010000434A1 (es) 2011-01-28

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000434A CL2010000434A1 (es) 2007-11-02 2010-04-30 Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.

Country Status (18)

Country Link
US (3) US8022048B2 (es)
EP (1) EP2215047B1 (es)
JP (1) JP5555634B2 (es)
KR (1) KR101344369B1 (es)
CN (1) CN101952241B (es)
AU (1) AU2008318423B2 (es)
BR (1) BRPI0817396C8 (es)
CA (1) CA2704780C (es)
CL (1) CL2010000434A1 (es)
CO (1) CO6280475A2 (es)
DK (1) DK2215047T3 (es)
ES (1) ES2443817T3 (es)
MX (1) MX2010004716A (es)
NZ (1) NZ585080A (es)
PL (1) PL2215047T3 (es)
PT (1) PT2215047E (es)
RU (1) RU2469728C2 (es)
WO (1) WO2009059188A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2461803B1 (en) * 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA202090889A1 (ru) * 2017-10-05 2020-08-19 Ресептор Холдингз, Инк. Травяные композиции с улучшенной биодоступностью
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
UY38480A (es) 2018-11-19 2020-06-30 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1998011900A2 (en) * 1996-09-18 1998-03-26 Sarill William J Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6255294B1 (en) 1998-12-28 2001-07-03 Allergy Limited Cyanocobalamin (vitamin B12) treatment in allergic disease
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
JP4799794B2 (ja) 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
KR101320817B1 (ko) 2001-06-01 2013-10-21 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
MXPA04001418A (es) 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
EP1545477A4 (en) * 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
EP1611084A1 (en) 2003-04-04 2006-01-04 DSM IP Assets B.V. Process for the manufacture of n-alkoxalyl-alaninates
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
BRPI0412458A (pt) 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
JP4716987B2 (ja) 2003-07-23 2011-07-06 ノバルティス アーゲー 骨関節症におけるカルシトニンの使用
ES2729825T3 (es) 2004-05-06 2019-11-06 Emisphere Tech Inc Formas poliméricas cristalinas de N-[8-(2-hidroxibenzoil)amino]caprilato monosódico
CA2575706A1 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US7354952B2 (en) 2005-11-04 2008-04-08 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
EP2215047A1 (en) 2010-08-11
US8557792B2 (en) 2013-10-15
CA2704780A1 (en) 2009-05-07
BRPI0817396C8 (pt) 2021-05-25
BRPI0817396B8 (pt) 2020-02-04
NZ585080A (en) 2012-05-25
AU2008318423B2 (en) 2013-12-05
CA2704780C (en) 2014-06-10
DK2215047T3 (da) 2014-02-03
PT2215047E (pt) 2014-01-20
EP2215047A4 (en) 2010-11-10
US8288360B2 (en) 2012-10-16
CN101952241A (zh) 2011-01-19
US20100016255A1 (en) 2010-01-21
KR101344369B1 (ko) 2013-12-24
US20110293589A1 (en) 2011-12-01
PL2215047T3 (pl) 2014-05-30
AU2008318423A1 (en) 2009-05-07
RU2469728C2 (ru) 2012-12-20
ES2443817T3 (es) 2014-02-20
BRPI0817396A2 (pt) 2015-04-07
RU2010118423A (ru) 2011-12-10
MX2010004716A (es) 2010-12-17
CO6280475A2 (es) 2011-05-20
US20130040910A1 (en) 2013-02-14
KR20100126263A (ko) 2010-12-01
CN101952241B (zh) 2014-06-11
BRPI0817396C1 (pt) 2020-11-17
US8022048B2 (en) 2011-09-20
JP2011502997A (ja) 2011-01-27
BRPI0817396B1 (pt) 2019-04-24
WO2009059188A1 (en) 2009-05-07
HK1146480A1 (en) 2011-06-10
EP2215047B1 (en) 2013-11-20
JP5555634B2 (ja) 2014-07-23

Similar Documents

Publication Publication Date Title
ZA202508806B (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JOP20200154A1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
PH12022550007A1 (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
BRPI0817396B8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
HN2008001666A (es) Derivados acidos de cicloalquilamino
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
ZA201901370B (en) Formulations for oral administration of active agents
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
JOP20240006A1 (ar) قرص يشتمل على ملح لحمض n-(8-(2-هيدروكسي بنزويل) أمينو) كبريليك
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.
PH12022550008A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
UY31826A (es) Compuesto peptídico y su uso
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
EA201201428A1 (ru) Наружное средство для лечения болезней суставов и мягких тканей
UY29256A1 (es) Uso de deirvados de acido ciclopropanoico sustituidos para producir medicamentos para tratar el síndrome metabólico
UY27193A1 (es) Glicina, n-(n-l-y glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones
CL2012001818A1 (es) Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis.
ES2173044B1 (es) Derivados de glicina, n-(n-l-gamma-glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.
AR095957A2 (es) Un compuesto derivado de piperidinilo, composición farmaceutica que lo comprende y sus usos para la preparación de un medicamento